安科生物(300009) - 300009安科生物投资者关系管理信息20260302

Group 1: Revenue Growth Drivers - The key revenue growth drivers for 2026 include Trastuzumab "Ansaiting," which is expected to exceed ¥100 million in sales in 2024 and continue significant growth in 2025. If not included in national procurement, the company will actively promote market layout for this product [1][2] - The long-acting follicle-stimulating hormone, exclusively represented by the company, has a potential national market size of over ¥4 billion. With only two competitors in the long-acting category, the product is expected to become a core offering, supported by national policies favoring fertility-related industries [2] Group 2: R&D Progress and Strategy - The company adopts an "independent innovation + external introduction" R&D model, collaborating with renowned scholars and experts to enhance its research capabilities. Ongoing clinical trials include "HuA21 injection," which has shown promising safety and efficacy in early studies and is moving towards Phase III trials [3][4] - The "AK2024 injection," targeting HER2, is currently in Phase I clinical trials, demonstrating superior synergistic effects compared to other treatments. The "HK010 injection," a dual antibody drug, has completed Phase II trials [3][4] Group 3: Strategic Collaborations and Market Positioning - The company is collaborating with Weisheng Pharmaceutical on the long-acting growth hormone "Lungpei," which has been approved for market entry. The product is positioned as a high-quality import, with plans for local production by 2028 [5] - The company’s subsidiary, Boshengji, is advancing its PA3-17 injection, which is in critical clinical trials and may become the first product in its field to market by the end of 2026 [6] Group 4: Innovations in Biotechnology - Boshengji is developing a dual-specific NK cell connector and a leading UCAR-Vδ1T product, which are expected to effectively target tumor heterogeneity [6] - Afana, another subsidiary, is focusing on mRNA vaccines for RSV and HPV, with its RSV mRNA vaccine being the first in China to complete Phase II clinical enrollment, showing excellent safety and efficacy [6]